Preliminary clinical experience with cis-diamminedichloroplatinum (II) (NSC 119875, CACP).
D000588:Amines / Q000009:adverse effects / Q000627:therapeutic use*; D000740:Anemia / Q000139:chemically induced; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001299:Audiometry; D001806:Blood Urea Nitrogen; D001853:Bone Marrow / Q000187:drug effects; D001854:Bone Marrow Cells; D002712:Chlorides / Q000009:adverse effects / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D006311:Hearing Disorders / Q000139:chemically induced; D006801:Humans; D007668:Kidney / Q000187:drug effects; D007970:Leukopenia / Q000139:chemically induced; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000188:drug therapy*; D010984:Platinum / Q000009:adverse effects / Q000627:therapeutic use* / Q000633:toxicity; D013921:Thrombocytopenia / Q000139:chemically induced; D013997:Time Factors; D014527:Uric Acid / Q000097:blood; D014839:Vomiting / Q000139:chemically induced
D000588:Amines; D000970:Antineoplastic Agents; D002712:Chlorides; D014527:Uric Acid; D010984:Platinum